CJC-1295 (No DAC) 10mg — Vial Spec, Reconstitution Math & COA

Technical Overview of the CJC-1295 (No DAC) 10mg Format

A 10mg vial of CJC-1295 (No DAC)—also designated in literature as Modified GRF (1-29)—contains ten milligrams of high-purity, lyophilized synthetic peptide prepared with a suitable lyoprotectant matrix. This specific unit mass is engineered primarily for research facilities running high-volume, multi-plate bioassays, automated assay platforms, or long-term animal models where maintaining consistency across experimental runs requires a single batch source.

Because CJC-1295 (No DAC) retains the rapid biological half-life of natural growth hormone-releasing hormone (GHRH) fragments, researchers frequently deploy it in studies requiring discrete, pulsatile GHRH receptor stimulation. Utilizing a 10mg mass allocation allows investigators to reconstitute a single master vial for high-density dilution series, minimizing vial-to-vial variance and simplifying assay setup.

Molecular Architecture and Receptor Binding Mechanism

CJC-1295 (No DAC) is a tetrasubstituted 29-amino acid peptide analog derived from human GHRH (1-29) amide. The primary sequence incorporates specific amino acid substitutions at positions 2 (D-Ala), 8 (Ala), 15 (Ala), and 27 (Leu). These structural alterations significantly enhance enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) cleavage relative to native GHRH (1-29), while preserving high binding affinity for the anterior pituitary GHRH receptor (GHRHR).

Preclinical studies suggest that upon binding to GHRHR, the peptide activates the intracellular adenylate cyclase pathway, driving cyclic adenosine monophosphate (cAMP) accumulation and protein kinase A (PKA) activation. In vitro data indicate that this signaling cascade triggers the regulated exocytosis of growth hormone (GH) without causing prolonged receptor desensitization or altering baseline physiological feedback mechanisms. In animal models, this action leads to episodic elevations of circulating GH and downstream hepatic stimulation of insulin-like growth factor 1 (IGF-1).

PX1 Research Catalog Specifications and Format Availability

PX1 Research supplies analytical-grade research compounds manufactured under strict Quality Management Systems (QMS) in USA-based facilities. While 10mg mass specifications are frequently utilized in large-scale research projects, researchers should note that standard catalog inventory for CJC-1295 No DAC is primarily offered in standardized 2mg and 5mg lyophilized vial sizes to optimize stability upon initial reconstitution.

Laboratories requiring 10mg mass configurations or custom bulk lyophilization lots for high-throughput screening can consult our full catalog of all peptides or contact our technical support division to establish a custom synthesis or wholesale procurement agreement. Regardless of total mass per unit, every batch supplied by PX1 Research undergoes rigorous testing in ISO 17025 accredited partner laboratories to guarantee precise content, purity, and freedom from contaminants.

Precision Reconstitution Math for a 10mg Lyophilized Mass

Accurate concentration calculations are vital when reconstituting a 10mg (10,000 mcg) cake of CJC-1295 (No DAC) to ensure reproducible dosing across experimental wells or test subjects. The total peptide mass must be completely dissolved in a measured volume of sterile diluent, such as Bacteriostatic Water (0.9% benzyl alcohol) or Sterile 0.9% Sodium Chloride.

To calculate working concentrations, apply the formula: Concentration (mg/mL) = Total Mass (mg) / Diluent Volume (mL). To assist in fast in-lab verification, researchers can utilize our online reconstitution calculator or reference the standardized volumetric calculations below:

1. Reconstitution with 1.0 mL Diluent: Adding 1.0 mL yields a concentration of 10.0 mg/mL (10,000 mcg/mL or 10 mcg per microliter [µL]). This highly concentrated solution is suitable for minimal-volume micro-injection setups or master stock preparation.

2. Reconstitution with 2.0 mL Diluent: Adding 2.0 mL yields a concentration of 5.0 mg/mL (5,000 mcg/mL or 5 mcg per µL). This medium-density concentration balances volumetric precision with efficient fluid transfer in standard pipette ranges.

3. Reconstitution with 3.0 mL Diluent: Adding 3.0 mL yields a concentration of 3.33 mg/mL (3,333 mcg/mL or 3.33 mcg per µL). This lower concentration is optimal when micro-dosing small animal models where higher volumetric resolution reduces pipetting error.

Laboratory Aliquoting and Working Solution Optimization

Because peptide stability degrades after liquid reconstitution, handling a single 10mg vial requires a deliberate aliquoting strategy. Repeated freeze-thaw cycles subject the peptide backbone to shear forces and ice-crystal formation that can alter secondary structure and reduce biological activity in cell culture assays.

Following initial dissolution, the stock solution should be partitioned under aseptic laminar flow conditions into sterile, low-binding polypropylene micro-centrifuge tubes. Aliquots should be sized to accommodate a single laboratory assay run or daily working volume, then immediately stored at -20°C or -80°C. Working vials kept at 2°C to 8°C should ideally be consumed within 14 to 21 days to prevent hydrophobic aggregation or hydrolysis.

Analytical Quality Control and Lot-Matched COA Protocols

To maintain rigorous scientific standards, every batch produced by PX1 Research is linked to a lot-matched Certificate of Analysis (COA). Researchers can independently verify product purity, identity, and physical parameters directly on our COA library page by cross-referencing their vial lot number.

Analytical evaluation relies on High-Performance Liquid Chromatography (HPLC) to confirm peptide purity exceeding 99.0% and Mass Spectrometry (MS) to verify molecular mass (theoretical MW: 3357.9 Da). Furthermore, every fill lot undergoes Bacterial Endotoxin Testing (LAL assay) to ensure levels remain strictly below < 0.01 EU/mg, preventing confounding inflammatory responses in sensitive cell culture or animal models.

Stability Dynamics, Temperature Limits, and Long-Term Storage

Lyophilized CJC-1295 (No DAC) displays high chemical stability when stored in dark, controlled thermal environments. Unreconstituted 10mg vials should be stored at -20°C for up to 24 months, or at 2°C to 8°C for up to 90 days without measurable degradation. Exposure to direct light, elevated humidity, and room temperature (>25°C) for extended periods must be avoided.

PX1 Research ships all research compounds in cold-chain compatible packaging from our California and Arizona fulfillment nodes. Same-day dispatch (Monday–Friday) ensures rapid delivery, protecting product integrity throughout transit. Upon arrival, vials must be placed immediately into temperature-controlled storage prior to reconstitution.

Comparative Analysis: CJC-1295 (No DAC) vs. Related Secretagogues

When designing protocols investigating the somatotropic axis, researchers frequently select between different GHRH analogs and growth hormone secretagogues. Comparing CJC-1295 (No DAC) with related peptides like Sermorelin and Ipamorelin highlights distinct pharmacokinetic and receptor-affinity profiles.

While Sermorelin represents the native 29-amino-acid GHRH sequence, CJC-1295 (No DAC) features chemical modifications that significantly decrease susceptibility to DPP-IV degradation in vitro, resulting in extended half-life in animal plasma. Conversely, Ipamorelin acts on an entirely distinct target—the ghrelin/growth hormone secretagogue receptor (GHS-R1a)—rather than the GHRH receptor. Consequently, researchers often co-administer CJC-1295 (No DAC) and Ipamorelin in preclinical models to explore synergistic intracellular signaling via concurrent cAMP/PKA and IP3/DAG pathway activation.

Preclinical Research Applications in Somatotropic Signaling

In vitro and animal models utilize CJC-1295 (No DAC) to examine diverse physiological outcomes downstream of pulsatile GH secretion. Primary focus areas in published literature include tissue repair kinetics, extracellular matrix remodeling, muscle protein synthesis signaling (via mTOR upregulation), and lipid metabolism pathways.

Researchers interested in expanding their experimental scope can access comprehensive literature reviews, trial parameters, and scientific documentation within the PX1 research library. These resources offer structured guidance for designing controlled laboratory protocols across various cell lines and preclinical research models.